CarcinoX Preventive Formulation Licensing & Collaboration Framework

  • Home
  • India
  • Kalna
  • CarcinoX Preventive Formulation Licensing & Collaboration Framework

CarcinoX Preventive Formulation

Licensing & Collaboration Framework 

CarcinoXโ„ข is a preventive formulation positioned for long-term prophylactic use.

https://www.facebook.com/share/1883Npwthd/
17/02/2026

https://www.facebook.com/share/1883Npwthd/

Phase-1 is about to start soon.

๐Ÿ“ข ๐— ๐—”๐—›๐—”๐— ๐—”๐—ก๐—”๐—กโ€“๐—š๐—น๐—ผ๐—ฏ๐—ฎ๐—น ๐—›๐—ผ๐—ป๐—ผ๐˜‚๐—ฟ๐˜€ ๐—ณ๐—ผ๐—ฟ ๐—›๐˜‚๐—บ๐—ฎ๐—ป ๐—˜๐˜…๐—ฐ๐—ฒ๐—น๐—น๐—ฒ๐—ป๐—ฐ๐—ฒ & ๐—–๐—ผ๐—ป๐˜€๐—ฐ๐—ถ๐—ผ๐˜‚๐˜€๐—ป๐—ฒ๐˜€๐˜€ ๐—˜๐˜ƒ๐—ผ๐—น๐˜‚๐˜๐—ถ๐—ผ๐—ป ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฒ
Honouring Minds that Elevate Humanity

๐— ๐—”๐—›๐—”๐— ๐—”๐—ก๐—”๐—ก is an international honours platform dedicated to recognising individuals who contribute to human excellence, ethical leadership, research advancement, social transformation, and the evolution of higher consciousness.

๐ŸŒ Human civilization is technologically advanced today, but is human consciousness developed in the same proportion?
This is the question that ๐— ๐—”๐—›๐—”๐— ๐—”๐—ก๐—”๐—กโ€“ Global Honours for Human Excellence & Consciousness Evolution 2026 has started its journey.

Honouring Minds that Elevate Humanity

๐— ๐—”๐—›๐—”๐— ๐—”๐—ก๐—”๐—ก โ€” a registered trust (Govt. of India DARPAN & MSME Registered) โ€” is dedicated to true human development through mental development education.
We would like to honor those whoโ€”
โœ” Working in human consciousness and moral development
โœ” Contributing to research and knowledge
โœ” Improving society through literature and art
โœ” Setting a unique example in human service
โœ” Remaining dedicated to the path of human development throughout their lives

๐Ÿ† Award Categories:
โ€ข ๐— ๐—”๐—›๐—”๐— ๐—”๐—ก๐—”๐—ก Human Consciousness & Integral Development Award
โ€ข ๐— ๐—”๐—›๐—”๐— ๐—”๐—ก๐—”๐—ก Lifetime Achievement in Human Advancement
โ€ข ๐— ๐—”๐—›๐—”๐— ๐—”๐—ก๐—”๐—ก Seva Ratna Award
โ€ข ๐— ๐—”๐—›๐—”๐— ๐—”๐—ก๐—”๐—ก Research Excellence Award
โ€ข ๐— ๐—”๐—›๐—”๐— ๐—”๐—ก๐—”๐—ก Award for Literature & Creative Arts
โ€ข ๐— ๐—”๐—›๐—”๐— ๐—”๐—ก๐—”๐—ก Order of Human Awakening (Inclusive Distinction)

๐Ÿ“Œ Nomination & Application Opening Soon ๐ŸŒ Global Participation Welcome
Let us recognise those who are shaping the future of humanity โ€” from within.

For more details, please visit the webPag:
๐— ๐—”๐—›๐—”๐— ๐—”๐—ก๐—”๐—ก โ€“ Global Honours for Human Excellence & Consciousness Evolution 2026
https://mahamanan-awards.blogspot.com/p/mahamanan-global-honours-for-human.html

WhatsApp: +91 8538805751

12/02/2026
CarcinoXโ„ข Preventive FormulationLicensing & Collaboration Framework (Confidential)Status: Formula is DND (Do Not Disclos...
04/02/2026

CarcinoXโ„ข Preventive Formulation
Licensing & Collaboration Framework (Confidential)
Status: Formula is DND (Do Not Disclose). This page defines licensing terms, responsibilities, and governance for prospective licensees.

1. Overview
CarcinoXโ„ข is a preventive formulation positioned for long-term prophylactic use. The formulation is proprietary and protected under confidentiality. Licensing is offered to qualified entities (pharma, nutraceutical, clinical research organizations) capable of executing regulated clinical development and IP protection.
Licensor: Inventor / Rights Holder (Confidential)
License Scope (Indicative):
Preventive oncology / risk-reduction domain
Human use (subject to regulatory approvals)
Territory-specific or global (as agreed)

2. Confidentiality & DND Status
The full formulation, process parameters, biomarkers, and rationale are DND.
Disclosure occurs only after ex*****on of NDA + Licensing Term Sheet.
No reverse engineering, decompilation, or analytical replication is permitted.
Breach of DND triggers immediate termination and liquidated damages.

3. Licensing Model
3.1 License Type
โ˜ Exclusive (Territory / Indication-bound)
โ˜ Co-exclusive
โ˜ Non-exclusive
3.2 Financial Structure (Indicative)
Upfront License Fee: Negotiable
Milestone Payments: Linked to clinical phases & approvals
Royalty: % on net sales (tiered)
Minimum Annual Commitment: Yes / No

4. Licensee Responsibilities (Mandatory)
The Licensee bears full responsibility for the following:

4.1 Clinical Development
Design, fund, and execute pre-clinical and clinical trials
Ethics committee approvals (IEC/IRB)
Compliance with ICH-GCP, local regulations
Trial registration (e.g., CTRI / ClinicalTrials.gov)

4.2 Regulatory Approvals
Dossier preparation and submissions
Engagement with national/international regulators
Post-marketing surveillance (if approved)

4.3 Patent & IP Protection
Filing, prosecution, and maintenance of patents
Territory-wise patent strategy
Defensive publications (if applicable)
All costs borne by Licensee
Note: Core IP ownership remains with Licensor unless explicitly assigned.

5. Licensor Rights & Support
Strategic scientific guidance (non-operational)
Periodic technical clarification (within NDA scope)
Right to audit development progress
Right to publish non-confidential, high-level outcomes (with consent)

6. Manufacturing & Quality (If Applicable)
GMP-compliant manufacturing mandatory
Stability, shelf-life, and quality validation by Licensee
No subcontracting without prior written approval

7. Branding & Use of Name
CarcinoXโ„ข trademark usage subject to brand guidelines
No modification of brand or claims without approval
Preventive claims must be regulator-approved

8. Reporting & Governance
Quarterly progress reports
Annual development roadmap review
Immediate notification of adverse events or regulatory actions

9. Term, Termination & Reversion
Initial Term: X years
Termination for:
DND/NDA breach
Failure to initiate trials within agreed timeline
Regulatory non-compliance
Upon termination:
All rights revert to Licensor
Data access terms as per agreement

10. Liability & Indemnity
Licensee assumes all clinical, regulatory, and commercial risk
Indemnifies Licensor against claims, adverse outcomes, or misuse

11. Expression of Interest (EOI)
Prospective licensees must submit:
Company profile & track record
Clinical trial capability
Patent & regulatory experience
Proposed territory & indication
Shortlisted entities will be invited for NDA ex*****on.

12. Disclaimer
This page is for discussion purposes only and does not constitute a binding offer.

Address

Kalna
713409

Website

Alerts

Be the first to know and let us send you an email when CarcinoX Preventive Formulation Licensing & Collaboration Framework posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram